Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer.

ABSTRACT: Despite advances in its treatment, lung cancer still represents the most common and lethal tumor. Because of that, efforts to decipher the pathophysiological actors that may promote lung tumor generation/progression are being made, with the final aim of establishing new therapeutic options. Using a transgenic mouse model, we formerly demonstrated that the sole activation of the MEK5/ERK5 MAPK route had a pathophysiological role in the onset of lung adenocarcinomas. Given the prevalence of that disease and its frequent dismal prognosis, our findings opened the possibility of targeting the MEK5/ERK5 route with therapeutic purposes. Here we have explored such possibility. We found that increased levels of MEK5/ERK5 correlated with poor patient prognosis in lung cancer. Moreover, using genetic

SUBMITTER: Sanchez-Fdez A 

PROVIDER: S-EPMC8371118 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature